Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fentanyl + midazolam is a combination therapy consisting of a potent synthetic opioid analgesic and a short-acting benzodiazepine. Fentanyl acts as a mu-opioid receptor agonist, providing rapid and effective analgesia, while midazolam serves as a positive allosteric modulator of the GABA-A receptor, inducing sedation and anxiolysis. This specific combination is being evaluated by the **University of Texas at Austin** for intranasal administration in pediatric patients. The primary goal of this formulation is to provide effective pain relief and reduce anxiety during minor surgical procedures, such as the repair of facial lacerations, offering a non-invasive alternative to intravenous sedation in the emergency department setting.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fentanyl + midazolam (84bf09).